News and Trends 17 Nov 2022 Startup Cradle raises $5.4M to design protein machines and cell factories with AI Cradle, a Dutch startup, has received €5.5 million ($5.4 million) in seed funding to further help scientists design and program proteins to produce a wide variety of everyday products including milk and meat. Cradle uses synthetic biology, adapting the genes of microorganisms such as bacteria and fungi, to create ‘cell factories’ that use programmable proteins […] November 17, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Nov 2022 Six biotech stocks trading below cash right now The biotech stock market is currently in a tough spot, with many companies facing suppressed valuations. We’ve listed six public companies trading with a market cap below their cash in hand. A range of factors are driving down company valuations in the public biotech market, such as soaring inflation, geopolitical instability and the threat of […] November 16, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Fooditive takes world first bee-free honey a step closer Large scale production trials of the first bee-free honey will start in the New Year thanks to Dutch-based ingredients company, Fooditive. The process of mass-producing a bio-identical honey means that the need to intensively farm honeybees will be eliminated and Fooditive aims to beat a scalable, provenanced supply. Not only will it provide the benefits […] November 15, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Nov 2022 ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […] November 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Lipum starts chronic inflammatory disease drug study Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Enzyre secures €12M series A funding to help hemophilia patients test from home Dutch company, Enzyre, which is developing ambulant diagnostic technology for blood coagulation testing, today (November 2) announced it has successfully raised €12 million ($11.9 million) in series A financing. The round was led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Ophthalmology biopharma company Oculis combines with EBAC Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named Oculis Holding SA and will work to accelerate the development […] October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Accelerated application for drug to help immunodeficiency submitted by Pharming A marketing authorization application (MAA) has been submitted by Dutch company Pharming Group, to the European Medicines Agency (EMA) for a rare, primary immunodeficiency in adults and adolescents 12 years and older. Activated phosphonide 3-kinase delta syndrome (APDS), first discovered in 2013, is caused by genetic variants in either one of two identified genes known […] October 11, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Oct 2022 Needle-free diabetes care: 7 devices that painlessly monitor blood sugar Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be […] October 7, 2022 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […] October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Kling Biotherapeutics doses first patient in advanced solid tumor trial Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care. KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Optics11 Life receives €5 million in funding for drug development and rollout of products Expanded offerings for drug development and regenerative medicines will be the focus of €5 million ($4.8 million) funding raised by Optics11 Life. The funding from Forward.ONE and returning investor, Value Creation Capital, was announced today (September 28) and will support the rollout of new products applying the company’s technology for experiments at scale requiring high-throughput […] September 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email